1. How to use GuruFocus - Tutorials
  2. What Is in the GuruFocus Premium Membership?
  3. A DIY Guide on How to Invest Using Guru Strategies
insider
insider
Articles 

Baker Bros. Advisors Lp Buys Incyte Corp, AveXis Inc, La Jolla Pharmaceutical Co, Sells AbbVie Inc, Derma Sciences Inc, Array BioPharma Inc

New York, NY, based Investment company Baker Bros. Advisors Lp buys Incyte Corp, AveXis Inc, La Jolla Pharmaceutical Co, Ascendis Pharma A/S, CymaBay Therapeutics Inc, AnaptysBio Inc, Dermira Inc, Jounce Therapeutics Inc, Stemline Therapeutics Inc, Tonix Pharmaceuticals Holding Corp, sells AbbVie Inc, Derma Sciences Inc, Array BioPharma Inc, Zogenix Inc, Alcobra during the 3-months ended 2017-03-31, according to the most recent filings of the investment company, Baker Bros. Advisors Lp. As of 2017-03-31, Baker Bros. Advisors Lp owns 111 stocks with a total value of $12 billion. These are the details of the buys and sells.

For the details of BAKER BROS. ADVISORS LP's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=BAKER+BROS.+ADVISORS+LP

These are the top 5 holdings of BAKER BROS. ADVISORS LP
  1. Incyte Corp (INCY) - 34,110,011 shares, 37.97% of the total portfolio. Shares added by 45.15%
  2. Seattle Genetics Inc (SGEN) - 45,715,556 shares, 23.93% of the total portfolio. Shares added by 0.01%
  3. ACADIA Pharmaceuticals Inc (ACAD) - 25,819,768 shares, 7.39% of the total portfolio.
  4. Alexion Pharmaceuticals Inc (ALXN) - 6,544,130 shares, 6.61% of the total portfolio. Shares added by 0.01%
  5. Genomic Health Inc (GHDX) - 13,770,982 shares, 3.61% of the total portfolio.
New Purchase: AnaptysBio Inc (ANAB)

Baker Bros. Advisors Lp initiated holdings in AnaptysBio Inc. The purchase prices were between $16.62 and $28.78, with an estimated average price of $23.3. The stock is now traded at around $23.72. The impact to the portfolio due to this purchase was 0.03%. The holdings were 150,000 shares as of 2017-03-31.

New Purchase: Jounce Therapeutics Inc (JNCE)

Baker Bros. Advisors Lp initiated holdings in Jounce Therapeutics Inc. The purchase prices were between $16.58 and $25.58, with an estimated average price of $21.19. The stock is now traded at around $15.50. The impact to the portfolio due to this purchase was 0.02%. The holdings were 100,000 shares as of 2017-03-31.

New Purchase: Tonix Pharmaceuticals Holding Corp (TNXP)

Baker Bros. Advisors Lp initiated holdings in Tonix Pharmaceuticals Holding Corp. The purchase prices were between $3.49 and $6.32, with an estimated average price of $5.13. The stock is now traded at around $4.13. The impact to the portfolio due to this purchase was 0.02%. The holdings were 449,500 shares as of 2017-03-31.

New Purchase: Windtree Therapeutics Inc (WINT)

Baker Bros. Advisors Lp initiated holdings in Windtree Therapeutics Inc. The purchase prices were between $1.13 and $1.69, with an estimated average price of $1.3. The stock is now traded at around $0.87. The impact to the portfolio due to this purchase was less than 0.01%. The holdings were 254,973 shares as of 2017-03-31.

New Purchase: BioPharmX Corp (BPMX)

Baker Bros. Advisors Lp initiated holdings in BioPharmX Corp. The purchase prices were between $0.38 and $0.55, with an estimated average price of $0.46. The stock is now traded at around $0.47. The impact to the portfolio due to this purchase was less than 0.01%. The holdings were 377,295 shares as of 2017-03-31.

Added: Incyte Corp (INCY)

Baker Bros. Advisors Lp added to the holdings in Incyte Corp by 45.15%. The purchase prices were between $102.32 and $152.66, with an estimated average price of $127.32. The stock is now traded at around $118.05. The impact to the portfolio due to this purchase was 11.81%. The holdings were 34,110,011 shares as of 2017-03-31.

Added: AveXis Inc (AVXS)

Baker Bros. Advisors Lp added to the holdings in AveXis Inc by 58.58%. The purchase prices were between $47.26 and $84, with an estimated average price of $61.9. The stock is now traded at around $70.88. The impact to the portfolio due to this purchase was 0.12%. The holdings were 500,000 shares as of 2017-03-31.

Added: La Jolla Pharmaceutical Co (LJPC)

Baker Bros. Advisors Lp added to the holdings in La Jolla Pharmaceutical Co by 2658.14%. The purchase prices were between $16.97 and $38.44, with an estimated average price of $25.53. The stock is now traded at around $26.56. The impact to the portfolio due to this purchase was 0.09%. The holdings were 379,134 shares as of 2017-03-31.

Added: Ascendis Pharma A/S (ASND)

Baker Bros. Advisors Lp added to the holdings in Ascendis Pharma A/S by 32.07%. The purchase prices were between $19.91 and $29.92, with an estimated average price of $25.27. The stock is now traded at around $24.00. The impact to the portfolio due to this purchase was 0.08%. The holdings were 1,351,463 shares as of 2017-03-31.

Added: CymaBay Therapeutics Inc (CBAY)

Baker Bros. Advisors Lp added to the holdings in CymaBay Therapeutics Inc by 357.05%. The purchase prices were between $1.6 and $4.3, with an estimated average price of $2.87. The stock is now traded at around $4.98. The impact to the portfolio due to this purchase was 0.04%. The holdings were 1,413,499 shares as of 2017-03-31.

Added: Dermira Inc (DERM)

Baker Bros. Advisors Lp added to the holdings in Dermira Inc by 27.27%. The purchase prices were between $27.98 and $38.03, with an estimated average price of $32.26. The stock is now traded at around $28.75. The impact to the portfolio due to this purchase was 0.03%. The holdings were 415,448 shares as of 2017-03-31.

Sold Out: AbbVie Inc (ABBV)

Baker Bros. Advisors Lp sold out the holdings in AbbVie Inc. The sale prices were between $60 and $66.55, with an estimated average price of $62.87.

Sold Out: Derma Sciences Inc (DSCI)

Baker Bros. Advisors Lp sold out the holdings in Derma Sciences Inc. The sale prices were between $5 and $7.03, with an estimated average price of $6.68.

Sold Out: Alcobra Ltd (ADHD)

Baker Bros. Advisors Lp sold out the holdings in Alcobra Ltd. The sale prices were between $0.94 and $2.52, with an estimated average price of $1.32.

Sold Out: Minerva Neurosciences Inc (NERV)

Baker Bros. Advisors Lp sold out the holdings in Minerva Neurosciences Inc. The sale prices were between $7.6 and $12.35, with an estimated average price of $9.71.

Sold Out: Ionis Pharmaceuticals Inc (IONS)

Baker Bros. Advisors Lp sold out the holdings in Ionis Pharmaceuticals Inc. The sale prices were between $37.93 and $54.7, with an estimated average price of $44.91.

Sold Out: Enanta Pharmaceuticals Inc (ENTA)

Baker Bros. Advisors Lp sold out the holdings in Enanta Pharmaceuticals Inc. The sale prices were between $27.72 and $36.05, with an estimated average price of $31.14.



Here is the complete portfolio of BAKER BROS. ADVISORS LP. Also check out:

1. BAKER BROS. ADVISORS LP's Undervalued Stocks
2. BAKER BROS. ADVISORS LP's Top Growth Companies, and
3. BAKER BROS. ADVISORS LP's High Yield stocks
4. Stocks that BAKER BROS. ADVISORS LP keeps buying

Rating: 0.0/5 (0 votes)

Comments

Please leave your comment:


GuruFocus has detected 3 Warning Signs with Incyte Corp $INCY.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.

Performances of the stocks mentioned by insider


User Generated Screeners


dxpakMini-Magic Screen
filmwatcherStable Dividend Growers
monomythJ Crew competition
WellrossFuture F Portfolio
marco.forzaniSHORT 2
pbarker4652 week low
sunnywhyWEI_ShortSqueeze
samuelbfoxMini-Magic Screen
MNVBen's last filter 1
dellmsftInsider CEO Buying Reid
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}
FEEDBACK